Human CD155/PVR(Poliovirus Receptor) ELISA Kit
Key features and details
- Specification:
- Sensitivity:
- Standard Curve Range:
- Standard Curve Gradient:
- Number of Incubations:
- Sample Volume:
- Assay type:
- Operation Duration:
-
Brand:
CAT.NO. : AEHY0155
RMB Please choose
RMB Please choose
Size:
Trail, Bulk size or Custom requests Please contact us
Product Details
Background
CD155 [also known as PVR (poliovirus receptor) and Necl-5 (nectin-like molecule-5)] is a 70 kDa type I transmembrane (TM) glycoprotein that is a member of the nectin-like (Necl) family of nectin-related molecules. Like nectins, Necl molecules are Ig superfamily members that contain three Ig-like extracellular domains, a TM segment, and a cytoplasmic tail. Unlike nectins, Necl molecules cannot interact with cytoplasmic afadin. While Nectins serve as cell adhesion molecules, the actual functions of most Necls are yet-to-be determined. CD155/PVR was originally isolated based on its ability to mediate polio virus attachment to host cells. The full-length (or CD155 alpha isoform) is synthesized as a 417 amino acid (aa) precursor that contains a 20 aa signal sequence, a 323 aa extracellular region, a 24 aa TM segment and a 50 aa cytoplasmic tail. The extracellular region contains one N-terminal V-type and two C2-type Ig-like domains. The V-type domain mediates polio virus binding. Three other isoforms exist, all of which retain the Ig-like domains. CD155δ is transmembrane with a shortened cytoplasmic tail of 25 aa. CD155 beta (352 aa) and CD155 gamma (344 aa) are 60‑65 kDa soluble forms that show removal of the TM segment and surrounding amino acids. The soluble forms will bind the polio virus (due to the presence of the V-type Ig domain) but afford no protection against polio infection because of low circulating levels. CD155 has been demonstrated to bind vitronectin, nectin-3, and DNAM-1. DNAM-1 binding promotes monocyte migration and NK cell killing. CD155 is expressed in all normal tissues and is highly expressed in tumor cells of epithelial and neuronal origin.
Typical data
|
ng/ml |
O.D. |
Average |
Corrected |
|
|
0.00 |
0.0084 |
0.0085 |
0.0085 |
|
|
0.41 |
0.0244 |
0.0238 |
0.0241 |
0.0157 |
|
1.23 |
0.0572 |
0.0551 |
0.0562 |
0.0477 |
|
3.70 |
0.1522 |
0.1557 |
0.1540 |
0.1455 |
|
11.11 |
0.4902 |
0.4839 |
0.4871 |
0.4786 |
|
33.33 |
1.4070 |
1.4170 |
1.4120 |
1.4036 |
|
100.00 |
3.0310 |
3.1030 |
3.0670 |
3.0586 |
|
300.00 |
3.8790 |
3.9340 |
3.9065 |
3.8981 |
Precision
|
Intra-assay Precision |
Inter-assay Precision |
|||||
|
Sample Number |
S1 |
S2 |
S3 |
S1 |
S2 |
S3 |
|
22 |
22 |
22 |
6 |
6 |
6 |
|
|
Average(ng/ml) |
6.0 |
32.6 |
126.4 |
5.3 |
30.0 |
119.7 |
|
Standard Deviation |
0.2 |
1.3 |
4.0 |
0.2 |
0.5 |
1.7 |
|
Coefficient of Variation(%) |
3.3 |
4.0 |
3.1 |
3.1 |
1.8 |
1.4 |
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human CD155/PVR(Poliovirus Receptor) into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 82% to 103% with an overall mean recovery of 91%.
The recovery ranged from 82% to 103% with an overall mean recovery of 91%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (ng/ml) | Detectable (%) | Mean of Detectable (ng/ml) |
|---|---|---|---|---|
| Serum | 30 | 571.24-1084.17 | 100 | 904.22 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of CD155/PVR(Poliovirus Receptor) in this assay. No medical histories were available for the donors.
New Products
